

Biology of Blood and Marrow Transplantation

journal homepage: www.bbmt.org

Clinical Research: Adult

Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease



Fevzi F. Yalniz¹, Mehrdad Hefazi¹, Kristen McCullough², Mark R. Litzow¹, William J. Hogan¹, Robert Wolf², Hassan Alkhateeb¹, Ankit Kansagra¹, Moussab Damlaj³, Mrinal M. Patnaik^{1,*}

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota

² Department of Pharmacy, Mayo Clinic, Rochester, Minnesota

³ Division of Hematology, King Abdulaziz University, Riyadh, Saudi Arabia

Article history: Received 30 January 2017 Accepted 1 May 2017

Key Words:

Acute graft-versus-host disease Allogeneic hematopoietic cell transplantation Tumor necrosis factor alpha blockade

ABSTRACT

Acute graft-versus-host disease (aGVHD) is the leading cause of morbidity and mortality after allogenic hematopoietic cell transplantation (HCT). Corticosteroids are the first-line treatment; however, less than onehalf of patients achieve durable remission. Studies suggest that TNF- α , a cytokine released from the bone marrow during conditioning, is involved in the pathogenesis of aGVHD. We retrospectively evaluated the outcome of anti-TNF- α therapy with infliximab in 35 patients with steroid refractory (SR) aGVHD. Infliximab was administered intravenously at 10 mg/kg for a median of 4 doses (range, 1 to 6) on a weekly basis. The overall response rates were 40% (17% complete response [CR], 23% partial response [PR]) at 4 weeks, 23% (9% CR, 14% PR) at 8 weeks, and 17% (all CR) at 12 weeks. Twenty-nine (83%) patients had infectious complications within 12 weeks of initiation of infliximab. These infections included 40 bacterial infections. Overall survival at 12 weeks and 6 months from the start of infliximab therapy was 37% (13 of 35) and 17% (6 of 35), respectively; with most deaths secondary to complications from GVHD and infections. In conclusion; the use of infliximab therapy in patients with SR-aGVHD is associated with a modest poorly sustained response along with a heightened risk of severe infections. Future studies with more effective and less toxic therapies are needed for these patients. © 2017 American Society for Blood and Marrow Transplantation.

INTRODUCTION

Acute graft-versus-host disease (aGVHD) is an important cause of morbidity and mortality in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Reported incidence rates range from 10% to 80%, depending upon prevalent risk factors [1]. Corticosteroids are the mainstay of treatment and response to steroids is a key predictor of outcome [2]. However, more than one-half of treated patients will be steroid refractory (SR), with mortality rates ranging between 50% and 60% [3-5]. There is no consensus on the optimal strategy for managing SR patients and it remains an area of unmet medical need. Second-line therapies, such as antithymocyte globulin (ATG) and monoclonal antibodies, have been studied in this setting, but outcomes, especially for advanced aGVHD, remain dismal [6-9].

Inflammatory cytokines are important mediators of aGVHD [10-12]. TNF- α released during the conditioning regimen is involved in the pathogenesis of aGVHD by activating

antigen-presenting cells, recruiting effector cells, and causing direct tissue damage [13,14]. Infliximab is a chimeric monoclonal antibody that binds both the soluble subunit and the membranebound precursor of TNF- α . Small retrospective case series have provided conflicting results with regard to efficacy in the setting of SR-aGVHD. In a pilot study assessing the efficacy of infliximab in patients with SR-aGVHD, Couriel et al. investigated a cohort of 21 patients and reported an overall response rate (ORR) of 67% [15]. This finding was supported by additional small retrospective studies [16-22]. A more recent study assessing infliximab salvage therapy in 52 patients reported a complete response (CR) of 15% [23], while a randomized, upfront, phase 3 study comparing infliximab with corticosteroids to corticosteroids alone in aGVHD did not show any benefit [24].

At our institution, infliximab is used for treatment of SR grades III and IV aGVHD. In this article, we report our experience using infliximab in a series of 35 consecutive patients with SR-aGVHD.

METHODS

Patients

Financial disclosure: See Acknowledgments on page 1484. * Correspondence and reprint requests: Mrinal M. Patnaik, MBBS, Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905.

E-mail address: patnaik.mrinal@mayo.edu (M.M. Patnaik).

After institutional review board approval, adult patients \geq 18 years of age who received infliximab therapy for SR-aGVHD from January 1, 2003 until

May 30, 2016 were identified thorough a retrospective review of our clinical database. The selection criteria included patients who presented both with classic aGVHD occurring within 100 days after HCT and persistent or late-onset aGVHD occurring after 100 days in the absence of features consistent with chronic GVHD (cGVHD). All relevant demographic, clinical, laboratory, and pathologic data were retrospectively abstracted.

Definitions

Acute GVHD was staged and graded according to the Glucksberg scale [25]. *Steroid refractoriness* was defined as any grade progression within 3 days of therapy onset or failure to achieve at least 1 grade improvement within 7 days of initiation of systemic steroids.

CR was defined as sustained resolution of all clinical signs of aGVHD; *partial response* (PR) was defined as an improvement in aGVHD stage in at least 1 of the initially involved organs without complete resolution and without worsening of severity in other affected organs; *no response* (NR) was defined as the same stage of GVHD in all organs or progression of aGVHD in any organ. *Overall response* was defined as either CR or PR. Those who achieved a response after additional agents beyond infliximab were also defined as NR to infliximab. *Overall survival* (OS) was calculated from the first day of infliximab therapy until the date of death from any cause. *Nonrelapse mortality* was defined as time to death without evidence of disease relapse.

Invasive fungal infections (IFI) were classified and defined according to the revised version of the European Organization for Research and Treatment of Cancer/Mycosis Study Group criteria [26].

Treatment and response evaluation

All patients signed a written consent for data collection and analysis. Patients were on antiviral prophylaxis with acyclovir or valacyclovir, antibiotic prophylaxis with penicillin (doxycycline for penicillin intolerance/ allergy) \pm levofloxacin/ciprofloxacin (only if absolute neutrophil count was <.5 x 10(9)/L), trimethoprim-sulfamethoxazole, and fungal prophylaxis either with an azole (voriconazole n = 27, 77%; posaconazole n = 4, 11%; fluconazole n = 2, 6%) or an echinocandin (caspofungin n = 1, 6%) at the start of infliximab therapy, according to the Mayo Clinic protocol for antimicrobial prophylaxis for active GVHD. Infliximab was dosed at 10 mg/kg intravenously on a weekly basis, with an initial plan for 4 doses. Additional doses were allowed at the discretion of the treating physician, based on response assessment.

Acute GVHD responses were evaluated retrospectively at 4 weeks, 8 weeks, and 12 weeks from the first day of infliximab administration or at the time of last follow-up, if occurring earlier than the stated time points. All infections detected from the first day of infliximab therapy until 12 weeks after completion of therapy were noted. Recurrent aGVHD and relapse of the underlying hematological malignancy were recorded until the date of death or last follow-up.

Statistics

Baseline patient, disease, and treatment-related variables were reported using descriptive statistics (counts, medians, and percentages). Survival analysis was performed using the Kaplan-Meier method. Univariate logistic regression models were utilized to assess the association between patient characteristics and treatment outcomes. The baseline and follow-up liver enzyme levels were compared using a paired *t*-test. Statistical analyses were performed using JMP Pro Version 11 (SAS Institute, Cary, NC) software.

RESULTS

Patient and Disease Characteristics

Thirty-five patients were treated with off-label use of infliximab for SR-aGVHD. The median age was 55 years (range, 35 to 68) and there were 23 males (66%). The most common indication for transplantation was acute leukemia (n = 14, 40%) followed by chronic lymphocytic leukemia (n = 9, 26%), multiple myeloma (n = 4, 11%), myelodysplastic syndrome (n = 3, 9%), myeloproliferative neoplasm (n = 2, 6%), chronic myelomonocytic leukemia (n = 2, 6%), and non-Hodgkin lymphoma (n = 1, 2%). One patient received a bone marrow graft (3%), while the remainder received peripheral blood (n = 34, 97%) grafts, with stem cell sources from matched related (n = 19, 54%), matched unrelated (n = 11, 31%), mismatched related (n = 1, 3%), or mismatched unrelated (n = 4, 11%) donors. There were no umbilical cord blood or haploidentical blood/ bone marrow recipients. Patients received pretransplantation conditioning with reduced-intensity regimens (n = 20, 57%)

Table 1

Patient Demographics and Transplantation Characteristics (n = 35)

CharacteristicValueAge at HCT, median (range), yr $55 (35-68)$ Gender, male $23 (66)$ Diagnosis $12 (34)$ Acute myeloid leukemia $12 (34)$ Chronic lymphocytic leukemia $9 (26)$ Myelodysplastic syndrome $3 (9)$ Myeloma $4 (11)$ Myeloproliferative neoplasms $2 (6)$ Other* $5 (14)$ Disease status at HCT $(R$ CR $11 (31)$ Not in CR $24 (69)$ ABO mismatch $6 (17)$ Matched $19 (54)$ Minor mismatch $6 (17)$ Major/bidirectional mismatch $10 (29)$ Donor type $Related$ Related $20 (57)$ Unrelated $15 (43)$ HLA match RIC RIC $20 (57)$ MA $15 (43)$ Donor/recipient sex $Female/male$ Female/male $7 (20)$ Other $28 (80)$ Stem cell source $Bone marrow$ Bone marrow $1 (3)$ Peripheral blood $34 (97)$ CMV status $D -/R +$ $D +/R -, D +/R +, $ or $D -/R +$ $27 (77)$ $D -/R 8 (23)$ GVHD prophylaxis $2 (6)$ Other $2 (6)$ Overall GVHD grade at the beginning of infliximab $5 (43)$ Grade 3 $15 (43)$	rutent Demographies and Hansplanation endracteristics (n = 55)	
Gender, male23 (66)Diagnosis12 (34)Acute myeloid leukemia9 (26)Myelodysplastic syndrome3 (9)Myelodysplastic syndrome3 (9)Myeloma4 (11)Myelogroliferative neoplasms2 (6)Other*5 (14)Disease status at HCT7CR11 (31)Not in CR24 (69)ABO mismatch6 (17)Major/bidirectional mismatch10 (29)Donor type7Related20 (57)Unrelated15 (43)HLA match30 (86)Mismatched*5 (14)Conditioning regimen7 (20)RIC20 (57)MA15 (43)Donor/recipient sex7 (20)Female/male7 (20)Other28 (80)Stem cell source800Bone marrow1 (3)Peripheral blood34 (97)CMV status17 (49)D+/R-, D+/R+, or D-/R+27 (77)D-/R-8 (23)GVHD prophylaxis26(6)Overall CVHD grade at the beginning of infliximab26(6)Overall CVHD grade at the beginning of infliximab5 (43)	Characteristic	Value
Diagnosis12 (34)Acute myeloid leukemia9 (26)Myelodysplastic syndrome3 (9)Myelodysplastic syndrome3 (9)Myeloproliferative neoplasms2 (6)Other*5 (14)Disease status at HCT CR CR11 (31)Not in CR24 (69)ABO mismatch19 (54)Matched19 (54)Minor mismatch6 (17)Major/bidirectional mismatch10 (29)Donor type $Related$ Related20 (57)Unrelated15 (43)HLA match $Related$ Matched30 (86)Mismatched [†] 5 (14)Conditioning regimen RIC RIC20 (57)MA15 (43)Donor/recipient sex $remale/male$ Female/male7 (20)Other28 (80)Stem cell source a Bone marrow1 (3)Peripheral blood34 (97)CMV status L $D+/R-, D+/R+, or D-/R+$ 27 (77) $D-/R-$ 8 (23)GVHD prophylaxis $C_{2}(6)$ Other2 (6)Overall CVHD grade at the beginning of infliximabGrade 315 (43)	Age at HCT, median (range), yr	55 (35-68)
Acute myeloid leukemia12 (34)Chronic lymphocytic leukemia9 (26)Myelodysplastic syndrome3 (9)Myelograft syndrome3 (9)Myeloproliferative neoplasms2 (6)Other*5 (14)Disease status at HCT $(R = 11 (31))$ R24 (69)ABO mismatch9 (54)Matched19 (54)Minor mismatch10 (29)Donor type $(R = 12 (34))$ Related20 (57)Unrelated15 (43)HLA match $(S = 12 (34))$ Matched30 (86)Mismatched [†] 5 (14)Conditioning regimen $(R = 20 (57))$ RIC20 (57)MA15 (43)Donor/recipient sex $(S = 12 (34))$ Female/male7 (20)Other28 (80)Stem cell source $(S = 13 (31))$ Bone marrow1 (3)Peripheral blood34 (97)CMV status $(S = 13 (31))$ D+/R-, D+/R+, or D-/R+27 (77)D-/R-8 (23)GVHD prophylaxis $(S = 12 (31))$ Cyclosporine ± MTX17 (49)Tacrolimus ± MTX16 (45)Other26 (6)Overall GVHD grade at the beginning of infliximab $(S = 13 (31))$	Gender, male	23 (66)
Chronic lymphocytic leukemia9 (26)Myelodysplastic syndrome3 (9)Myeloma4 (11)Myeloproliferative neoplasms2 (6)Other*5 (14)Disease status at HCT (R) CR11 (31)Not in CR24 (69)ABO mismatch (G) Matched19 (54)Minor mismatch6 (17)Major/bidirectional mismatch10 (29)Donor type $(Related)$ Related20 (57)Unrelated15 (43)HLA match $(S43)$ Matched30 (86)Mismatched*5 (14)Conditioning regimen (RC) RIC20 (57)MA15 (43)Donor/recipient sex $(S43)$ Female/male7 (20)Other28 (80)Stem cell source $(S43)$ Bone marrow1 (3)Peripheral blood34 (97)CMV status $D -/R +$ $D +/R -, D +/R +, or D -/R +$ 27 (77) $D -/R -$ 8 (23)GVHD prophylaxis $(G + 10)$ Cyclosporine ± MTX17 (49)Tacrolimus ± MTX16 (45)Other26 (6)Overall GVHD grade at the beginning of infliximab $(G + 3)$ Grade 315 (43)	Diagnosis	
Myelodysplastic syndrome3 (9)Myeloma4 (11)Myeloproliferative neoplasms2 (6)Other5 (14)Disease status at HCT $(11 (31))$ CR11 (31)Not in CR24 (69)ABO mismatch (617) Major/bidirectional mismatch10 (29)Donor type (617) Related20 (57)Unrelated15 (43)HLA match (14) Matched30 (86)Mismatched5 (14)Conditioning regimen (13) RIC20 (57)MA15 (43)Donor/recipient sex (13) Female/male7 (20)Other28 (80)Stem cell source (13) Bone marrow1 (3)Peripheral blood34 (97)CMV status (24) D+/R-, D+/R+, or D-/R+27 (77)D-/R-8 (23)GVHD prophylaxis (26) Other2 (6)Overall GVHD grade at the beginning of infliximab (543)	Acute myeloid leukemia	12 (34)
Myeloma4 (11)Myeloproliferative neoplasms2 (6)Other*5 (14)Disease status at HCT (131) CR11 (31)Not in CR24 (69)ABO mismatch (617) Matched19 (54)Minor mismatch6 (17)Major/bidirectional mismatch10 (29)Donor type (2057) Related20 (57)Unrelated15 (43)HLA match $(30 (86))$ Mismatched†5 (14)Conditioning regimen $(20 (57))$ RIC20 (57)MA15 (43)Donor/recipient sex $(20 (57))$ Female/male7 (20)Other28 (80)Stem cell source $(34 (97))$ CMV status $(21 (32))$ D+/R-, D+/R+, or D-/R+27 (77)D-/R-8 (23)GVHD prophylaxis (26) Other26(6)Overall CVHD grade at the beginning of infliximab (543)	Chronic lymphocytic leukemia	9(26)
Myeloproliferative neoplasms $2 (6)$ Other* $5 (14)$ Disease status at HCT CR CR $11 (31)$ Not in CR $24 (69)$ ABO mismatch $9 (54)$ Matched $19 (54)$ Minor mismatch $6 (17)$ Major/bidirectional mismatch $10 (29)$ Donor type $Related$ Related $20 (57)$ Unrelated $15 (43)$ HLA match $30 (86)$ Mismatched* $5 (14)$ Conditioning regimen RIC RIC $20 (57)$ MA $15 (43)$ Donor/recipient sex $Female/male$ Female/male $7 (20)$ Other $28 (80)$ Stem cell source B Bone marrow $1 (3)$ Peripheral blood $34 (97)$ CMV status U $D+/R-, D+/R+, or D-/R+$ $27 (77)$ $D-/R 8 (23)$ GVHD prophylaxis $C_{2}(6)$ Other $2 (6)$ Overall CVHD grade at the beginning of infliximab $5 (43)$	Myelodysplastic syndrome	3 (9)
Other* $5(14)$ Disease status at HCT(RCR11 (31)Not in CR24 (69)ABO mismatch19 (54)Matched19 (54)Minor mismatch6 (17)Major/bidirectional mismatch10 (29)Donor type(Eastername)Related20 (57)Unrelated15 (43)HLA match(S14)Matched30 (86)Mismatched [†] 5 (14)Conditioning regimen(Conditioning regimen)RIC20 (57)MA15 (43)Donor/recipient sex(S16)Female/male7 (20)Other28 (80)Stem cell source(S16)Bone marrow1 (3)Peripheral blood34 (97)CMV status(CMV status)D+/R-, D+/R+, or D-/R+27 (77)D-/R-8 (23)GVHD prophylaxis(S2)Cyclosporine ± MTX17 (49)Tacrolimus ± MTX16 (45)Other2 (6)Overall CVHD grade at the beginning of infliximabGrade 315 (43)	Myeloma	4(11)
Disease status at HCT (11) CR 11 (31) Not in CR 24 (69) ABO mismatch (11) Matched 19 (54) Minor mismatch 6 (17) Major/bidirectional mismatch 10 (29) Donor type (11) Related 20 (57) Unrelated 15 (43) HLA match (14) Matched 30 (86) Mismatched [†] 5 (14) Conditioning regimen (13) RIC 20 (57) MA 15 (43) Donor/recipient sex (20) Female/male 7 (20) Other 28 (80) Stem cell source (3) Bone marrow 1 (3) Peripheral blood 34 (97) CMV status $D + R - D + R +, \text{ or } D - R + $ $D + R - D + R +, \text{ or } D - R + $ 27 (77) $D - R - $ 8 (23) GVHD prophylaxis (26) Other 2 (6) Overall CVHD grade at the beginning of infliximab (64) <td>Myeloproliferative neoplasms</td> <td>2(6)</td>	Myeloproliferative neoplasms	2(6)
CR 11 (31) Not in CR 24 (69) ABO mismatch 9 Matched 19 (54) Minor mismatch 6 (17) Major/bidirectional mismatch 10 (29) Donor type 20 (57) Related 20 (57) Unrelated 15 (43) HLA match 30 (86) Mismatched [†] 5 (14) Conditioning regimen 11 (3) RIC 20 (57) MA 15 (43) Donor/recipient sex 7 (20) Female/male 7 (20) Other 28 (80) Stem cell source 8 Bone marrow 1 (3) Peripheral blood 34 (97) CMV status D D+/R-, D+/R+, or D-/R+ 27 (77) D-/R- 8 (23) GVHD prophylaxis 24 (64) Cyclosporine ± MTX 17 (49) Tacrolimus ± MTX 16 (45) Other 2 (6) Overall GVHD grade at the beginning of infliximab 15 (43)	Other*	5(14)
Not in CR $24 (69)$ ABO mismatch19 (54)Matched19 (54)Minor mismatch6 (17)Major/bidirectional mismatch10 (29)Donor type20 (57)Related20 (57)Unrelated15 (43)HLA match30 (86)Mismatched†5 (14)Conditioning regimen7 (20)RIC20 (57)MA15 (43)Donor/recipient sex7 (20)Female/male7 (20)Other28 (80)Stem cell source $34 (97)$ CMV status $D + R -, D + /R +, or D - /R +$ 27 (77)D-/R-8 (23)GVHD prophylaxis $17 (49)$ Tacrolimus \pm MTX17 (49)Tacrolimus \pm MTX16 (45)Other2 (6)Overall GVHD grade at the beginning of infliximab $5 (43)$	Disease status at HCT	
ABO mismatch19 (54)Matched19 (54)Minor mismatch6 (17)Major/bidirectional mismatch10 (29)Donor type20 (57)Related20 (57)Unrelated15 (43)HLA match30 (86)Mismatched [†] 5 (14)Conditioning regimen20 (57)RIC20 (57)MA15 (43)Donor/recipient sex20 (57)Female/male7 (20)Other28 (80)Stem cell source34 (97)CMV status1 (3)Peripheral blood34 (97)CMV status $D+/R-, D+/R+, or D-/R+$ 27 (77)D-/R-8 (23)GVHD prophylaxis17 (49)Tacrolimus ± MTX16 (45)Other26 (5)Overall GVHD grade at the beginning of infliximab15 (43)	CR	11 (31)
Matched19 (54)Minor mismatch6 (17)Major/bidirectional mismatch10 (29)Donor typeRelated20 (57)Unrelated15 (43)HLA matchMatched30 (86)Mismatchedt5 (14)Conditioning regimenRIC20 (57)MA15 (43)Donor/recipient sexFemale/male7 (20)Other28 (80)Stem cell sourceBone marrow1 (3)Peripheral blood34 (97)CMV statusD+/R-, D+/R+, or D-/R+27 (77)D-/R-8 (23)GVHD prophylaxisCyclosporine ± MTX17 (49)Tacrolimus ± MTX16 (45)Other26 (6)Overall GVHD grade at the beginning of infliximabGrade 315 (43)	Not in CR	24(69)
Minor mismatch 6 (17)Major/bidirectional mismatch10 (29)Donor type $20 (57)$ Related20 (57)Unrelated15 (43)HLA match $30 (86)$ Mismatched [†] $5 (14)$ Conditioning regimen RIC RIC20 (57)MA15 (43)Donor/recipient sex $7 (20)$ Other28 (80)Stem cell source $34 (97)$ CMV status $D^+/R^-, D^+/R^+, \text{ or } D^-/R^+$ $27 (77)$ $D^-/R^ 8 (23)$ GVHD prophylaxis $C_{20}(65)$ Other $2 (6)$ Overall GVHD grade at the beginning of infliximab $T_0 (43)$	ABO mismatch	
Major/bidirectional mismatch $10(29)$ Donor type $10(29)$ Related $20(57)$ Unrelated $15(43)$ HLA match $30(86)$ Matched $30(86)$ Mismatched [†] $5(14)$ Conditioning regimen $10(29)$ RIC $20(57)$ MA $15(43)$ Donor/recipient sex $7(20)$ Other $28(80)$ Stem cell source $34(97)$ CMV status $D+/R-, D+/R+, \text{ or } D-/R+$ $D+/R-, D+/R+, \text{ or } D-/R+$ $27(77)$ $D-/R 8(23)$ GVHD prophylaxis $17(49)$ Tacrolimus ± MTX $17(49)$ Tacrolimus ± MTX $16(45)$ Other $22(6)$ Overall GVHD grade at the beginning of infliximab $15(43)$	Matched	19(54)
Donor type 20 (57) Related 20 (57) Unrelated 15 (43) HLA match 30 (86) Matched 30 (86) Mismatched [†] 5 (14) Conditioning regimen 15 (43) RIC 20 (57) MA 15 (43) Donor/recipient sex Female/male Female/male 7 (20) Other 28 (80) Stem cell source Bone marrow Bone marrow 1 (3) Peripheral blood 34 (97) CMV status D D+/R-, D+/R+, or D-/R+ 27 (77) D-/R- 8 (23) GVHD prophylaxis 2 Cyclosporine ± MTX 17 (49) Tacrolimus ± MTX 16 (45) Other 2 (6) Overall GVHD grade at the beginning of infliximab (6) Grade 3 15 (43)	Minor mismatch	6(17)
Donor type 20 (57) Related 20 (57) Unrelated 15 (43) HLA match 30 (86) Matched 30 (86) Mismatched [†] 5 (14) Conditioning regimen 15 (43) RIC 20 (57) MA 15 (43) Donor/recipient sex Female/male Female/male 7 (20) Other 28 (80) Stem cell source Bone marrow Bone marrow 1 (3) Peripheral blood 34 (97) CMV status D D+/R-, D+/R+, or D-/R+ 27 (77) D-/R- 8 (23) GVHD prophylaxis 2 Cyclosporine ± MTX 17 (49) Tacrolimus ± MTX 16 (45) Other 2 (6) Overall GVHD grade at the beginning of infliximab (6) Grade 3 15 (43)	Major/bidirectional mismatch	10(29)
Unrelated $15 (43)$ HLA match 30 (86) Mismatched [†] $5 (14)$ Conditioning regimen $15 (43)$ RIC $20 (57)$ MA $15 (43)$ Donor/recipient sex $7 (20)$ Other $28 (80)$ Stem cell source 800 Bone marrow $1 (3)$ Peripheral blood $34 (97)$ CMV status $D+/R-, D+/R+, or D-/R+$ $D+/R-, D+/R+, or D-/R+$ $27 (77)$ $D-/R 8 (23)$ GVHD prophylaxis $Cyclosporine \pm MTX$ $Cyclosporine \pm MTX$ $17 (49)$ Tacrolimus $\pm MTX$ $16 (45)$ Other $2 (6)$ Overall GVHD grade at the beginning of infliximab $Grade 3$		~ /
HLA match $(100)^{10}$ Matched $30(86)$ Mismatched† $5(14)$ Conditioning regimen $1000000000000000000000000000000000000$	Related	20(57)
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Unrelated	15(43)
Mismatched [†] 5 (14) Conditioning regimen	HLA match	. ,
Mismatched [†] 5 (14) Conditioning regimen	Matched	30(86)
$\begin{array}{c} \mbox{Conditioning regimen} & & & & & \\ \mbox{RIC} & & & 20 (57) \\ \mbox{MA} & & & 15 (43) \\ \mbox{Donor/recipient sex} & & & & \\ \mbox{Female/male} & & & 7 (20) \\ \mbox{Other} & & & 28 (80) \\ \mbox{Stem cell source} & & & & \\ \mbox{Bone marrow} & & 1 (3) \\ \mbox{Peripheral blood} & & 34 (97) \\ \mbox{CMV status} & & & \\ \mbox{D+} \mbox{R-} \mbox{D+} \mbox{R+}, \mbox{or D-} \mbox{R+} & & 27 (77) \\ \mbox{D-} \mbox{R-} & & 8 (23) \\ \mbox{GVHD prophylaxis} & & & \\ \mbox{Cyclosporine \pm \mbox{MTX} & & 17 (49) \\ \mbox{Tacrolimus \pm \mbox{MTX} & & 16 (45) \\ \mbox{Other} & & & 2 (6) \\ \mbox{Overall GVHD grade at the beginning of infliximab} \\ \mbox{Grade } 3 & & 15 (43) \\ \end{array}$	Mismatched [†]	
$\begin{array}{cccc} RIC & 20(57) \\ MA & 15(43) \\ \hline Donor/recipient sex \\ Female/male & 7(20) \\ Other & 28(80) \\ \hline Stem cell source \\ Bone marrow & 1(3) \\ Peripheral blood & 34(97) \\ \hline CMV status & \\ D+/R-, D+/R+, or D-/R+ & 27(77) \\ D-/R- & 8(23) \\ \hline GVHD prophylaxis & \\ Cyclosporine \pm MTX & 17(49) \\ Tacrolimus \pm MTX & 16(45) \\ Other & 2(6) \\ \hline Overall GVHD grade at the beginning of infliximab \\ \hline Grade 3 & 15(43) \\ \hline \end{array}$	Conditioning regimen	~ /
$\begin{array}{ccc} MA & 15 \left(43 \right) \\ Donor/recipient sex & & & \\ Female/male & 7 \left(20 \right) \\ Other & 28 \left(80 \right) \\ Stem cell source & & \\ Bone marrow & 1 \left(3 \right) \\ Peripheral blood & 34 \left(97 \right) \\ CMV status & & \\ D+/R-, D+/R+, or D-/R+ & 27 \left(77 \right) \\ D-/R- & 8 \left(23 \right) \\ GVHD prophylaxis & & \\ Cyclosporine \pm MTX & 17 \left(49 \right) \\ Tacrolimus \pm MTX & 16 \left(45 \right) \\ Other & 2 \left(6 \right) \\ Overall GVHD grade at the beginning of infliximab \\ Grade 3 & 15 \left(43 \right) \\ \end{array}$		20(57)
Female/male 7 (20) Other 28 (80) Stem cell source $28 (80)$ Bone marrow 1 (3) Peripheral blood 34 (97) CMV status $27 (77)$ D+/R-, D+/R+, or D-/R+ 27 (77) D-/R- 8 (23) GVHD prophylaxis $2(6)$ Cyclosporine ± MTX 17 (49) Tacrolimus ± MTX 16 (45) Other 2 (6) Overall GVHD grade at the beginning of infliximab $3(23)$ Grade 3 15 (43)	MA	
Other 28 (80) Stem cell source Bone marrow 1 (3) Peripheral blood 34 (97) CMV status D+/R-, D+/R+, or D-/R+ 27 (77) D-/R- 8 (23) GVHD prophylaxis Cyclosporine ± MTX 17 (49) Tacrolimus ± MTX 16 (45) Other 2 (6) Overall GVHD grade at the beginning of infliximab Grade 3 15 (43)	Donor/recipient sex	. ,
Stem cell source Image: Constraint of the system of the sys	Female/male	7(20)
Bone marrow 1 (3) Peripheral blood 34 (97) CMV status 27 (77) D+/R-, D+/R+, or D-/R+ 27 (77) D-/R- 8 (23) GVHD prophylaxis 7 (49) Cyclosporine \pm MTX 16 (45) Other 2 (6) Overall GVHD grade at the beginning of infliximab 5 (43)	Other	28 (80)
Peripheral blood $34(97)$ CMV status $12000000000000000000000000000000000000$	Stem cell source	
$\begin{array}{c} {\sf CMV \ status} \\ {\sf D}+/{\sf R}-, {\sf D}+/{\sf R}+, {\rm or}\ {\sf D}-/{\sf R}+ & 27\ (77) \\ {\sf D}-/{\sf R}- & 8\ (23) \\ {\sf GVHD \ prophylaxis} \\ {\sf Cyclosporine \pm MTX} & 17\ (49) \\ {\sf Tacrolimus \pm MTX} & 16\ (45) \\ {\sf Other} & 2\ (6) \\ {\sf Overall \ GVHD \ grade \ at \ the \ beginning \ of \ infliximab} \\ {\sf Grade \ 3} & 15\ (43) \end{array}$	Bone marrow	1(3)
$\begin{array}{ccc} D + /R -, D + /R +, \mbox{ or } D - /R + & 27 \ (77) \\ D - /R - & 8 \ (23) \\ \hline GVHD \ prophylaxis \\ Cyclosporine \pm MTX & 17 \ (49) \\ Tacrolimus \pm MTX & 16 \ (45) \\ Other & 2 \ (6) \\ \hline Overall \ GVHD \ grade \ at \ the \ beginning \ of \ infliximab \\ \hline Grade \ 3 & 15 \ (43) \\ \end{array}$	Peripheral blood	34 (97)
D-/R-8 (23)GVHD prophylaxis7Cyclosporine ± MTX17 (49)Tacrolimus ± MTX16 (45)Other2 (6)Overall GVHD grade at the beginning of infliximab5 (43)Grade 315 (43)	CMV status	
GVHD prophylaxis 17 (49) Cyclosporine ± MTX 16 (45) Tacrolimus ± MTX 16 (45) Other 2 (6) Overall GVHD grade at the beginning of infliximab 5 (43)	D+/R-, D+/R+, or D-/R+	27(77)
$\begin{array}{llllllllllllllllllllllllllllllllllll$	D-/R-	8 (23)
Tacrolimus ± MTX16 (45)Other2 (6)Overall GVHD grade at the beginning of infliximabGrade 315 (43)	GVHD prophylaxis	
Other 2 (6) Overall GVHD grade at the beginning of infliximab Grade 3 15 (43)	Cyclosporine ± MTX	17 (49)
Overall GVHD grade at the beginning of infliximab Grade 3 15 (43)	Tacrolimus ± MTX	16(45)
Grade 3 15 (43)	Other	2(6)
Grade 3 15 (43)	Overall GVHD grade at the beginning of infliximab	• •
		15(43)
Glade 4 20 (37)	Grade 4	20 (57)

Data presented are n (%) unless otherwise indicated.

RIC indicates reduced-intensity conditioning; MA, myeloablative; CMV, cytomegalovirus; D/R, donor/recipient; MTX, methotrexate.

* Other diagnosis were acute bilineal leukemia, acute lymphoblastic leukemia, primary myelofibrosis, non-Hodgkin lymphoma.

[†] Four patients were 9/10 and 1 patient was8/10 matched.

and myeloablative regimens (n = 15, 43%). Primary GVHD prophylaxis was with the following: (1) cyclosporine combined with either mycophenolate mofetil (MMF) (n = 8, 23%) or methotrexate (n = 7, 20%), (2) tacrolimus combined either with methotrexate (n = 16, 46%) or sirolimus (n = 1, 3%), or (3) prednisone combined with either cyclosporine (n = 2, 6%) or MMF (n = 1, 3%). Patient and transplantation characteristics are summarized in Table 1.

GVHD and Treatment Response

The median time to onset of aGVHD was 43 (range, 17 to 154) days after transplantation (Table 2). Initial treatment was started at a median of 3 (range, 0 to 12) days after aGVHD onset, with an initial prednisone-equivalent corticosteroid dose of 1 mg/kg per day (n = 13, 37%) or 2 mg/kg per day (n = 22, 63%), at the discretion of the treating physician, and any prior treatment with calcineurin inhibitors (n = 18, 50%), MMF (n = 9, 27%), or sirolimus (n = 1, 3%) was continued.

Infliximab was administered as second-line therapy (n = 28, 80%) at a median of 17 (range, 6 to 50) days after the initiation of corticosteroids and as third-line therapy (n = 7, 20%)

Download English Version:

https://daneshyari.com/en/article/5524380

Download Persian Version:

https://daneshyari.com/article/5524380

Daneshyari.com